Suven Pharmaceuticals Ltd on Wednesday (February 12) reported a 77.1% year-on-year (YoY) jump in net profit at ₹82.9 crore for Q3FY25 over ₹46.8 crore in the year-ago period. Revenue from operations surged 39.8% to 307.2 crore against ₹219.8 crore in the corresponding period of FY24.
| Company | Value | Change | %Change |
|---|
At the operating level, EBITDA (earnings before interest, tax, depreciation, and amortisation) zoomed 78.2% YoY to ₹117.8 crore over ₹66 crore. The EBITDA margin expanded significantly to 38.4% versus 30.1% in Q3FY24.
Also Read: ITD Cementation Q3 Results | Net profit up 11% to ₹87 crore; order book at ₹19,893 crore
Suven Pharmaceuticals reported strong growth in the third quarter of FY25, driven primarily by its pharma CDMO segment, which posted a 101% year-on-year (YoY) increase. This growth was supported by continued R&D and business development efforts. The company’s gross margins for the quarter stood at 71.5%, while adjusted EBITDA margins came in at 38.7%.
For the first nine months of FY25, Suven Pharma incurred a capital expenditure of ₹938 million. The company generated ₹1.33 billion in free cash flow and maintained a cash and bank balance of ₹2.82 billion, reflecting its strong financial position.
In the pharma CDMO (contract development and manufacturing organisation) segment, Suven Pharma saw a twofold YoY increase in requests for quotations (RFQs) for 9M FY25, indicating sustained demand across different stages, supported by favourable macroeconomic trends.
The company added two new molecules during the quarter — one progressing to phase 3 and another directly included in phase 3 as a lateral addition — bringing the total number of active phase 3 projects to 15, covering nine molecules.
Also Read: Bharat Forge Q3 Results | Net profit, revenue, margin down; declares dividend
The specialty chemicals (SpecChem) CDMO segment showed signs of recovery as expected, following a period of decline in Q2. The company remains optimistic about continued improvement in this segment going forward.
The results came after the close of the market hours. Shares of Suven Pharmaceuticals Ltd ended at ₹1,050.10, down by ₹33.05, or 3.05%, on the BSE.
